 Augmenta Bioworks and TFF Pharmaceuticals Inc NASDAQ: TFFP have announced positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody, AUG-3387, binds to and neutralizes the SARS-CoV-2 Delta variant B.1.617.2. The companies have selected a final formulation of AUG-3387 that will be used to complete in vivo preclinical efficacy studies in the coming weeks and will proceed with toxicology studies by the end of 2021. 